Accéder au contenu
Merck

Deletion of Aurora kinase A prevents the development of polycystic kidney disease in mice.

Nature communications (2024-01-09)
Ming Shen Tham, Denny L Cottle, Allara K Zylberberg, Kieran M Short, Lynelle K Jones, Perkin Chan, Sarah E Conduit, Jennifer M Dyson, Christina A Mitchell, Ian M Smyth
RÉSUMÉ

Aurora Kinase A (AURKA) promotes cell proliferation and is overexpressed in different types of polycystic kidney disease (PKD). To understand AURKA's role in regulating renal cyst development we conditionally deleted the gene in mouse models of Autosomal Dominant PKD (ADPKD) and Joubert Syndrome, caused by Polycystin 1 (Pkd1) and Inositol polyphosphate-5-phosphatase E (Inpp5e) mutations respectively. We show that while Aurka is dispensable for collecting duct development and homeostasis, its deletion prevents cyst formation in both disease models. Cross-comparison of transcriptional changes implicated AKT signaling in cyst prevention and we show that (i) AURKA and AKT physically interact, (ii) AURKA regulates AKT activity in a kinase-independent manner and (iii) inhibition of AKT can reduce disease severity. AKT activation also regulates Aurka expression, creating a feed-forward loop driving renal cystogenesis. We find that the AURKA kinase inhibitor Alisertib stabilises the AURKA protein, agonizing its cystogenic functions. These studies identify AURKA as a master regulator of renal cyst development in different types of PKD, functioning in-part via AKT.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
VX-680, ≥98% (HPLC)